COVID 19: Nirmatrelvir, Omikron BA 2, NVX CoV2373 - Prof. Sester und Prof. Gärtner (Homburg)

Prof. Dr. Martina Sester und Prof. Dr. Barbara Gärtner (Homburg, Deutschland) erläutern in einem Update Gespräch neue Aspekte zur Epidemiologie, Prävention und Therapie von COVID-19

2:10 Epidemiologie: Omikron BA.2 Variante
12:51 Impfung: NVX-CoV2373 [Nuvaxovid; Novavax]
38:23 Antivirale Therapie: Nirmatrelvir und Ritonavir [Paxlovid]

Das Gespräch wurde am 28.02.2022 geführt. Moderatoren: Prof. Dr. Dr. Sören Becker (Homburg) und Prof. Dr. Gunnar Heine (Frankfurt am Main).

Diskutierte Studien:

Daichi Yamasoba et al.
Virological characteristics of SARS-CoV-2 BA.2 variant

Möglicher Einsatz der neutralisierenden monoklonalen Antikörper in Abhängigkeit von der diagnostizierten SARS-CoV-2-Virusvariante

Heath PT et al.; 2019nCoV-302 Study Group.
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine.
N Engl J Med. 2021 doi: 10.1056/NEJMoa2107659

Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L, Lalloo U, Masilela MSL, Moodley D, Hanley S, Fouche L, Louw C, Tameris M, Singh N, Goga A, Dheda K, Grobbelaar C, Kruger G, Carrim-Ganey N, Baillie V, de Oliveira T, Lombard Koen A, Lombaard JJ, Mngqibisa R, Bhorat AE, Benadé G, Lalloo N, Pitsi A, Vollgraaff PL, Luabeya A, Esmail A, Petrick FG, Oommen-Jose A, Foulkes S, Ahmed K, Thombrayil A, Fries L, Cloney-Clark S, Zhu M, Bennett C, Albert G, Faust E, Plested JS, Robertson A, Neal S, Cho I, Glenn GM, Dubovsky F, Madhi SA; 2019nCoV-501 Study Group.
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.
N Engl J Med. 2021 doi: 10.1056/NEJMoa2103055.

Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, Plested JS, Zhu M, Cloney-Clark S, Zhou H, Smith G, Patel N, Frieman MB, Haupt RE, Logue J, McGrath M, Weston S, Piedra PA, Desai C, Callahan K, Lewis M, Price-Abbott P, Formica N, Shinde V, Fries L, Lickliter JD, Griffin P, Wilkinson B, Glenn GM.
Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.
N Engl J Med. 2020 doi: 10.1056/NEJMoa2026920.

Dunkle LM et al.; 2019nCoV-301 Study Group.
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.
N Engl J Med. 2022 doi: 10.1056/NEJMoa2116185.

Wadman M.
The Long Shot
Science 2020

Nirmatrelvir/ritonavir use: Managing clinically significant drug-drug interactions with transplant immunosuppressants
Lange et al., Am J Transplant Preprint 2022

Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, Martín-Quirós A, Caraco Y, Williams-Diaz A, Brown ML, Du J, Pedley A, Assaid C, Strizki J, Grobler JA, Shamsuddin HH, Tipping R, Wan H, Paschke A, Butterton JR, Johnson MG, De Anda C; MOVe-OUT Study Group.
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.
N Engl J Med. 2021 doi: 10.1056/NEJMoa2116044

Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, Oguchi G, Ryan P, Nielsen BU, Brown M, Hidalgo A, Sachdeva Y, Mittal S, Osiyemi O, Skarbinski J, Juneja K, Hyland RH, Osinusi A, Chen S, Camus G, Abdelghany M, Davies S, Behenna-Renton N, Duff F, Marty FM, Katz MJ, Ginde AA, Brown SM, Schiffer JT, Hill JA; GS-US-540-9012 (PINETREE) Investigators.
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.
N Engl J Med. 2022 doi: 10.1056/NEJMoa2116846.

Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M, Hendrick VM, Damle B, Simón-Campos A, Pypstra R, Rusnak JM; EPIC-HR Investigators.
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.
N Engl J Med. 2022
doi: 10.1056/NEJMoa2118542.

José R. Arribas et al.
Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19
NEJM Evid 2022 DOI: 10.1056/EVIDoa2100044